Reducing myocardial infarct size: challenges and future opportunities

Area of Science:

• Cardiology
• Translational Medicine
• Biomedical Engineering

Background:

• Acute ST-segment elevation myocardial infarction (STEMI) carries significant mortality and morbidity despite timely primary percutaneous coronary intervention (PPCI).
• Myocardial reperfusion injury, encompassing cardiomyocyte death and microvascular dysfunction during reperfusion, is a critical but often overlooked therapeutic target.
• Existing cardioprotective strategies have shown promise in reducing infarct size in early studies but have struggled to demonstrate improved clinical outcomes.

Purpose of the Study:

• To review the challenges in clinical cardioprotection research for STEMI patients.
• To highlight emerging therapies for mitigating myocardial reperfusion injury.
• To identify future strategies for reducing myocardial infarct size and preventing heart failure post-STEMI.

Main Methods:

• Review of existing literature on cardioprotective therapies for STEMI.
• Analysis of challenges in translating cardioprotective strategies from preclinical to clinical settings.
• Exploration of novel mechanical and pharmacological approaches targeting myocardial reperfusion injury.

Main Results:

• Significant challenges persist in demonstrating clinical benefit from cardioprotective therapies despite evidence of infarct size reduction in proof-of-concept studies.
• Myocardial reperfusion injury remains a key determinant of adverse outcomes in STEMI patients.
• Future research directions focus on innovative therapies to address this unmet clinical need.

Conclusions:

• Despite advances in reperfusion therapy, myocardial reperfusion injury significantly contributes to poor outcomes in STEMI.
• Overcoming the challenges in clinical cardioprotection research is crucial for developing effective treatments.
• Targeting myocardial reperfusion injury holds promise for reducing infarct size and preventing heart failure in STEMI patients.